GSK2256098

Status: Currently a NF2 Clinical Trial

Index

1. Basic Information
2. Sources

Source:

1. "GSK2256098" National Center for Biotechnology Information. PubChem Compound Database; CID=46214930, https://pubchem.ncbi.nlm.nih.gov/compound/46214930
2. Alvarez-Breckenridge, Christopher, and Priscilla K. Brastianos. "SMO mutant olfactory groove meningiomas-the next in line for targeted therapy." Neuro-Oncology 19.3 (2017): 305-306.
   Source: https://academic.oup.com/neuro-oncology/article-abstract/19/3/305/3045157 DOI: 10.1093/neuonc/now302


3. Serrels, Alan, and Margaret C. Frame. "FAK goes nuclear to control antitumor immunity-a new target in cancer immuno-therapy." Oncoimmunology 5.4 (2016): e1119356.
   Source: (select PDF to read in full) | DOI: 10.1080/2162402X.2015.1119356


4. Mulholland, Paul, et al. "Atnt-06 Evaluation of The Safety Of Gsk2256098 And Pharmacokinetics Of 11c-Gsk2256098 In Patients With Recurrent Glioblastoma By Positron Emission Tomography (Pet) Imaging." Neuro-oncology 17.suppl_5 (2015): v11-v11.
   Source: https://academic.oup.com/neuro-oncology/article/17/suppl_5/v11/2765358/ATNT-05INTRAOPERATIVE-INTRAPARENCHYMAL-INJECTION | DOI: 10.1093/neuonc/nov205.05


5. Zhang, Jianliang, et al. "A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells." Cell Cycle 13.19 (2014): 3143-3149.
   Source: http://www.tandfonline.com/doi/abs/10.4161/15384101.2014.949550 | DOI: 10.4161/15384101.2014.949550


6. Soria, Jean-Charles, et al. "A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors." Annals of Oncology 27.12 (2016): 2268-2274.
   Source: https://academic.oup.com/annonc/article-abstract/27/12/2268/2736353 | DOI: 10.1093/annonc/mdw427


7. MDE - Med Chem Express. "GSK2256098."
   Source: http://www.medchemexpress.com/gsk2256098.html?gclid=Cj0KEQjwzYDMBRC1-JHJ7pPU278BEiQAwCv6JvSZEOZ-FIeo4gJniXqejnj7XoQ6FbgzcxBww2CoRoEaAgqH8P8HAQ


8. "A small molecule FAK kinase inhibitor, GSK2256098, inhibits growth and survival of pancreatic ductal adenocarcinoma cells." Cell Cycle. 13(19):3143-9. (2014)
   Source: https://www.ncbi.nlm.nih.gov/pubmed/25486573 | DOI: 10.4161/15384101.2014.949550.


9. "PTEN Expression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer." Mol Cancer Ther. (6):1466-1475. (Released: June 2014 | Update: Apr 2015)
   Source: https://www.ncbi.nlm.nih.gov/pubmed/25833835 | DOI: doi: 10.1158/1535-7163.MCT-14-1077.